20 documents found, page 1 of 2

LENT score in prognostic assessment of malignant pleural effusion – the impact ...

Introduction: Malignant pleural effusion (MPE) is a common manifestation in patients with advanced lung cancer. The LENT score was developed as a risk stratification system to predict the survival of these patients. However, following the discovery of molecular markers and a new era of personalized therapy, prognostic estimation became a challenging exercise. The aim of this study was to evaluate the performanc...

Comprehensive Evaluation of Peripheral Immunodynamics in Advanced Non-Small Cel...

Introduction: Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has transformed the treatment landscape for advanced non-small cell lung cancer (NSCLC). Despite significant benefits for some patients, durable responses are limited to 20%–30% of cases, necessitating predictive biomarkers for better therapeutic guidance. While tumor-based markers such as PD-L1 expression and tumor mutational burden...

Lung cancer study group - 25 years

Lung Cancer Screening in Portugal: A PULMONALE Pilot Project

N/a.; N/a.

Cancro do pulmão e cura

2013 e a imunoterapia em neoadjuvância no estádio precoce

Neutrophil-to-lymphocyte ratio as a prognostic marker in highly PD-L1 expressin...

Introduction and objectives: The neutrophil-lymphocyte ratio (NLR) has been proposed to assess advanced stage non-small cell lung cancer (aNSCLC) response to immunotherapy, given the easy availability and low cost. The aim of our study was to evaluate the relationship between NLR at baseline, after the 3rd and 6th treatment cycles, and progression free survival (PFS) and overall survival (OS), in a population w...

New approaches in RET and MET in NSCLC

The era of precision medicine has resulted in the identification of several genomic alterations that can be targeted with novel therapies. In lung adenocarcinomas, a histology that accounts for nearly 50% of all cases of lung cancer, a few genomic targets have been linked with effective targeted therapies. For patients with advanced-stage lung adenocarcinomas, molecular testing is now a standard part of diagnos...

O caso clínico

Editorial